Compare SSTK & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | CTMX |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.2M | 596.2M |
| IPO Year | 2012 | 2015 |
| Metric | SSTK | CTMX |
|---|---|---|
| Price | $18.77 | $4.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $25.00 | $6.50 |
| AVG Volume (30 Days) | 218.9K | ★ 2.1M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | ★ 66.87 | 50.22 |
| EPS | ★ 1.69 | 0.24 |
| Revenue | ★ $1,020,010,000.00 | $113,631,000.00 |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $11.14 | $17.49 |
| Revenue Growth | ★ 13.06 | N/A |
| 52 Week Low | $14.35 | $0.40 |
| 52 Week High | $38.80 | $4.62 |
| Indicator | SSTK | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 56.75 |
| Support Level | $17.92 | $3.78 |
| Resistance Level | $19.58 | $4.20 |
| Average True Range (ATR) | 0.79 | 0.23 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.40 | 72.39 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.